ANTHELMIN PLUS XL TABLETS FOR DOGS

Nchi: Ayalandi

Lugha: Kiingereza

Chanzo: HPRA (Health Products Regulatory Authority)

Viambatanisho vya kazi:

FEBANTEL, PYRANTEL EMBONATE, PRAZIQUANTEL

Inapatikana kutoka:

Krka, d.d., Novo mesto

ATC kanuni:

QP52AC55

INN (Jina la Kimataifa):

FEBANTEL, PYRANTEL EMBONATE, PRAZIQUANTEL

Kipimo:

175/504/525

Dawa fomu:

Tablets

Dawa ya aina:

CAM-Companion Animal Medicine

Kundi la matibabu:

Canine

Eneo la matibabu:

Febantel, combinations

Matibabu dalili:

Endoparasiticide

Idhini hali ya:

Authorised

Idhini ya tarehe:

2015-05-01

Tabia za bidhaa

SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Anthelmin Plus XL Tablets for dogs
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains:
ACTIVE SUBSTANCES:
Praziquantel
175 mg
Pyrantel embonate
504 mg
Febantel
525 mg
EXCIPIENTS:
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Tablets.
Oval, biconvex tablets with bevelled edges and scored on both sides.
Slightly greenish-yellow.
The tablets can be divided into equal halves.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs (large and extra large size)
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment of mixed infestations with the following roundworms
and tapeworms in adult dogs:
Nematodes
Ascarids:_ Toxocara canis_,_ Toxascaris leonina_ (late immature forms
and mature forms)
Hookworms:_ Uncinaria stenocephala_,_ Ancylostoma caninum_ (adults)
Cestodes
Tapeworms:_ Taenia_ spp.,_ Dipylidium caninum_
4.3 CONTRAINDICATIONS
Do not use simultaneously with piperazine compounds.
Do not use in animals with a known hypersensitivity to the active
substance or to any of excipients.
Do not exceed the stated dose when treating pregnant bitches.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Fleas serve as intermediate hosts for one common type of tapeworm –_
Dipylidium caninum_. Tapeworm infestation is
certain to re-occur unless control of intermediate hosts such as
fleas, mice etc is undertaken.
Parasite resistance to any particular class of anthelmintic may
develop following frequent, repeated use of an
anthelmintic of that class.
H
E
A
L
T
H
P
R
O
D
U
C
T
S
R
E
G
U
L
A
T
O
R
Y
A
U
T
H
O
R
I
T
Y
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___
___